The upgrade from Raymond James is a positive signal for Regeneron Pharmaceuticals. The new rating of Outperform suggests that the analyst believes the company will outperform the market, which could lead to an increase in the stock price. The price target of $950 also indicates a significant upside potential from the current price level.